The trial is a randomized, double-blind safety and efficacy trial in which Excellarate is topically administered once or twice over the course of the study, with a goal of complete ulcer closure at 12 weeks or earlier.
Thomas Serena, director of NewBridge Medical Research, said: “The Excellarate topical gel, using Gene Activated Matrix technology is designed to provide release of the platelet-derived growth factor BB protein, which stimulates angiogenesis (the growth of new blood vessels) and granulation tissue formation, the building blocks for a variety of wound healing processes.”